|
M. James Barrett, Ph.D., General Partner, New Enterprise Associates |
| Dr. Barrett has served as a Director since December 2002 and as Chairman of the Board since January 2003. Dr. Barrett is a general partner of New Enterprise Associates (NEA), a venture capital management firm. He specializes in biotechnology and works with members of NEA's medical and life sciences investment group on medical devices, healthcare information systems and healthcare services companies. Dr. Barrett is currently on the boards of Cardioxyl Pharmaceuticals, CoGenesys, Inc., GlycoMimetics, Inc. Inhibitex, Macroflux Corporation, Nucleonics, Inc., Peptimmune, Pharmion Corporation, Ruxton Pharmaceuticals, Inc., Sensors for Medicine and Science, Supernus Pharmaceuticals, Inc. Targacept, YM Biosciences, and he formerly served on the board of MedImmune, Inc. purchased by AstraZeneca in June 2007. Prior to joining NEA in September 2001, Dr. Barrett served as Founder/Chairman/CEO of Sensors for Medicine and Science (1997 - 2001) where he remains Chairman. Prior to that, he was Chairman/CEO of Genetic Therapy (1987 - 1995), President/CEO of Life Technologies (1985 - 1987), and President/CEO of Bethesda Research Labs (1982 - 1983). Prior to 1982, Dr. Barrett worked in various divisions of SmithKline. Dr. Barrett received a Ph.D. in Biochemistry at the University of Tennessee, a Masters in Business Administration from the University of Santa Clara, and a Bachelor of Science in Chemistry from Boston College. |
|
|
R. Gordon Douglas, Jr., M.D., President, Merck Vaccines (Retired) |
| Dr. Douglas has served as a Director since January 2003. Dr. Douglas was President of Merck Vaccines, responsible for the research, development, manufacturing, and marketing of Merck's vaccine products until May 1999. He grew the vaccine business from $300 million to $1.2 billion, launched four new products, invested heavily in manufacturing facilities as well as research and development, and expanded the business globally. Prior to joining Merck in 1989, Dr. Douglas had a distinguished career as a physician and academician, specializing in infectious diseases. From 1982 to 1990, he was a Professor of Medicine and Chairman of the Department of Medicine at Cornell University Medical College and Physician in Chief of New York Hospital. He also served as Head of the Infectious Disease Unit at the University of Rochester School of Medicine. Dr. Douglas currently acts as Consultant to the Vaccine Research Center at the National Institute of Health and serves on the Boards of Directors of several biotech companies and non-profits interested in vaccines and world health. Dr. Douglas is a graduate of Princeton University and Cornell University Medical College. He received his medical staff training at New York Hospital and Johns Hopkins Hospital. |
|
|
Richard Douglas, Ph.D., Sr. Vice President, Corporate Development, Genzyme Corporation |
| Dr. Douglas has served as a Director since January 2002. Dr. Douglas has over 25 years of biotechnology experience having served in Corporate Development roles at Genzyme Corporation since 1989. He is currently Senior Vice President Corporate Development and a Corporate Officer of Genzyme Corporation. As a leader of Genzyme's Corporate Development team, Dr Douglas has been involved in numerous acquisitions, licenses, joint ventures and strategic alliances. From 1982 until its merger with Genzyme Corporation in 1989, Dr. Douglas served in Science and Corporate Development capacities at Integrated Genetics. Dr. Douglas was a postdoctoral fellow at the California Institute of Technology. He received a Ph.D. from the University of California, Berkeley in biochemistry and a B.S. in chemistry from the University of Michigan. |
|
|
Stanley C. Erck, President and CEO, Iomai Corporation |
| Mr. Erck has served as President, Chief Executive Officer, Treasurer and Director since May 2000. Mr. Erck applies over 25 years of management experience in the healthcare and biotechnology industry to shepherd the development and commercialization of the TCI technology. Mr. Erck has worked at Baxter International, Procept, and Integrated Genetics. In addition, as a CEO, he has managed the process of developing companies from private funding through an initial public offering. Mr. Erck has a B.S. from the University of Illinois and an M.B.A. from the University of Chicago. |
|
|
Thomas Martin Vernon, Jr., M.D., Vice President, Policy, Public Health & Medical, Affairs, Merck Vac |
| Dr. Vernon joined the Board in 2006. Dr. Vernon served Merck & Co.'s vaccine division as Vice President for Policy, Public Health and Medical Affairs until 2004. Since then, he has consulted on public health and vaccine policy affairs for Chiron Corp., MedImmune Inc. and Digene Corp. Dr. Vernon has extensive experience in public health, both during this decade-long tenure at Merck and in his previous experience as director of health and human services at the Pew Charitable Trusts and Executive Director of the Colorado Department of Health. He served as president of the Association of State and Territorial Health Officials and current serves as the chairman of boards of directors of the American Social Health Association and the National Center for Healthy Housing. Dr. Vernon is a member of the CDC Foundation National Advocacy Council and has served on the board of directors of the Partnership for Prevention and the National Center for Genome Resources. A graduate of Harvard Medical School, Dr. Vernon is board-certified in internal medicine. |
|
|
F. Weller Meyer, Chairman, President and Chief Executive Officer, Acacia Federal Savings Bank |
| Mr. Meyer, a member of the Board since 2006, is the Chairman, President and Chief Executive Officer, Acacia Federal Savings Bank. He has led Acacia Federal for almost two decades, overseeing its rise from a bank with assets of $43 million to a $1.33 billion institution. In addition to serving as Chairman, Mr. Meyer is also a member of the bank's Executive, Investment and Loan Committees. He is the chairman of the board of the American's Community Bankers, a national banking trade association, and has testified before Congress on issues of legislation and banking regulations. (ADD: Mr Meyer is also a member of the Thrift Institutions Advisory Council (TIAC) to the Federal Reserve and will serve as vice president of the Council in 2007. In 1998 he was first appointed a member of the TIAC and in 2000 served as president of the key financial advisory group. The published author of five books on mortgage and real estate finance, Mr. Meyer graduated from the University of Maryland and completed graduate studies at the American University and the University of Maryland. |
|
|
|
|
|
